Journal: eLife

Article Title: Allosteric inhibition of the T cell receptor by a designed membrane ligand

doi: 10.7554/eLife.82861

Figure Lengend Snippet:

Article Snippet: TCR β , Cell Signaling Technology , 77046 , 1:2000 (WB).

Techniques:

Journal: Frontiers in Medicine

Article Title: PD-1 combined with TRBC1 and pan-T cell antibodies for robustly monitoring angioimmunoblastic T-cell lymphoma

doi: 10.3389/fmed.2022.962428

Figure Lengend Snippet: The most common aberrancies of pan-T cell antigens in AITL. (A) PB specimen in which neoplastic CD4+ T cells had bright CD45 and PD-1 expression, and diminished CD4 expression, lack of CD3, CD7, and TRBC1 with slightly larger side scatter. The same immunophenotyping was observed in BM, PB, and LN specimens. (B) FNA sample in which CD4+ aberrant T cells had bright CD4, CD2, and PD-1 expression, CD200 was positive, CD5, and CD45 were diminished; CD3, CD7, and TRBC1 were absent; Side scatter was enlarged.

Article Snippet: PD-1 (EH12.2H7, BioLegend, APC), CD10, TRBC1 (JOVI.1, Caprico biotechnologies, FITC) and some pan-T cell antibodies (such as CD3, CD4, CD5, CD7, and CD8) were placed in an additional tube to confirm or exclude a supposed PTCL diagnosis and for patients with an equivocal clinical history or immunophenotyping.

Techniques: Expressing

Journal: Frontiers in Medicine

Article Title: PD-1 combined with TRBC1 and pan-T cell antibodies for robustly monitoring angioimmunoblastic T-cell lymphoma

doi: 10.3389/fmed.2022.962428

Figure Lengend Snippet: Flow cytometric findings in non-T cell lymphoma. (A) CD4+ T cells with CD10 and bright PD-1 expression were observed in follicular lymphoma. (B) CD4+ T cells with CD200 and bright PD-1 expression were seen in tuberculous granuloma. (C) Expansion of CD4+T cells with bright PD-1 expression was present in nodular lymphocyte-predominant Hodgkin lymphoma. (D) CD4+ T cells with distinctive bright PD-1 expression were observed in reactive follicular hyperplasia. TRBC1 was polyclonal in these populations.

Article Snippet: PD-1 (EH12.2H7, BioLegend, APC), CD10, TRBC1 (JOVI.1, Caprico biotechnologies, FITC) and some pan-T cell antibodies (such as CD3, CD4, CD5, CD7, and CD8) were placed in an additional tube to confirm or exclude a supposed PTCL diagnosis and for patients with an equivocal clinical history or immunophenotyping.

Techniques: Expressing

Journal: Frontiers in Medicine

Article Title: PD-1 combined with TRBC1 and pan-T cell antibodies for robustly monitoring angioimmunoblastic T-cell lymphoma

doi: 10.3389/fmed.2022.962428

Figure Lengend Snippet: Some AITL immunophenotyping could not be detected by the T-cell screen tube. (A,D,E,F) show BM specimens. (B,C) show tissue samples. (A) Aberrant T cells were CD3+, CD4+, and CD10+ with bright PD-1 expression, and CD7 was partially expressed. (B) Neoplastic T cells were CD4+, CD7+, and CD10+ with slightly diminished CD3 and CD5 expression and bright PD-1 expression. (C) Tumor cells were CD3+, CD5+, CD7+, and CD200+ with diminished CD4 expression and bright CD2, CD56, and PD-1 expression, and CD10 was negative (not shown). (D) Abnormal T cells were CD3+, CD4+, CD5+, and CD200+ with bright CD7 and PD-1 expression, and CD10 was negative. (E) An extremely low ratio of CD7 negative T cells was CD3+, CD4+, and CD10+ with bright CD5 and PD-1 expression. The immunophenotyping of neoplastic T cells shifted over time (E,F) before and after therapy, respectively. TRBC1 did not show polyclonal expression in these populations.

Article Snippet: PD-1 (EH12.2H7, BioLegend, APC), CD10, TRBC1 (JOVI.1, Caprico biotechnologies, FITC) and some pan-T cell antibodies (such as CD3, CD4, CD5, CD7, and CD8) were placed in an additional tube to confirm or exclude a supposed PTCL diagnosis and for patients with an equivocal clinical history or immunophenotyping.

Techniques: Expressing